Consensus or Controversy, Issue 2: Controversial Issues in the Use of Next-Generation Endocrine Therapy and Immunotherapy in the Management of Metastatic Castration-Resistant Prostate Cancer
To see the complete question and investigator responses, move your mouse over the related topic.
Click the "Select Faculty Commentary" button to review full commentary (login required).
LN = lymph node; PD = progressive disease; sip-T = sipuleucel-T; enz = enzalutamide; abi = abiraterone
*At the time of this interview, enzalutamide was not approved in Europe for patients with metastatic |
|||||||
